ACP
TEVA icon

Aviance Capital Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Aviance Capital Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-5,615
Closed -$212K – 224
2013
Q3 		$212K Buy
+5,615
New +$219K 0.1% 194

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
MIP
Mondrian Investment Partners London, United Kingdom $6.69B AUM
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $30.5B AUM 29.95% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Aviance Capital Partners's TEVA Position: Q4 2013 in Review

Aviance Capital Partners sold out of Teva Pharmaceuticals (TEVA) in Q4 2013, closing a stake of 5,615 shares — an estimated $212K sold.

Aviance Capital Partners first reported a position in TEVA in Q3 2013 and held it in 1 quarter. The position peaked at $212K in Q3 2013. 727 funds tracked by Wall St. Rank hold TEVA as of Q4 2013.

  • Aviance Capital Partners reported no remaining Teva Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Aviance Capital Partners sold 5,615 Teva Pharmaceuticals shares in Q4 2013, an estimated $212K.
  • Aviance Capital Partners first reported a position in Teva Pharmaceuticals in Q3 2013 and held it in 1 quarter.
  • Aviance Capital Partners's Teva Pharmaceuticals position peaked at $212K in Q3 2013.
  • 727 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2013.

Based on Aviance Capital Partners's 13F filing for Q4 2013, filed 7 Feb 2014.